Login Register Cart 0
Generic placeholder image

Current Nanomedicine

Editor-in-Chief

ISSN (Print): 2468-1873
ISSN (Online): 2468-1881

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Development of In-situ Gel of Bupropion Hydrochloride-loaded Chitosan Nanoparticles using an Inotropic Gelation Method for Smoking Cessation via Nose to Brain: In-vitro and Ex-vivo Characterization and Evaluation

Author(s): Raghav Sharma* and Bijal Prajapati*

Volume 14, Issue 1, 2024

Published on: 14 September, 2023

Page: [54 - 64] Pages: 11

DOI: 10.2174/2468187313666230914121457

Price: $65

Abstract

Introduction: Tobacco use is the leading preventable cause of various diseases, disabilities, and death. It is estimated that 480000 deaths annually are attributed to cigarette smoking, including secondhand smoke exposure. The treatment of brain disorders is particularly challenging due to the presence of a variety of formidable obstacles to delivering drugs selectively and effectively to the brain. The blood-brain barrier (BBB) and first-pass metabolism constitute the major obstacle to the uptake of drugs into the brain following systemic administration. Intranasal delivery offers a non-invasive and convenient method to bypass the BBB and avoid first-pass metabolism, which leads to the delivery of therapeutics directly to the brain.

Objective: The objective of this study was to develop an In-situ gel of Bupropion Hydrochloride-loaded chitosan nanoparticles using the inotropic gelation method for Smoking Cessation via the nose to the brain to improve the bioavailability of Bupropion Hydrochloride, avoiding first-pass metabolism and bypassing Blood Brain Barrier.

Methods: Fourier transform infrared spectroscopy (FTIR) was used to determine the identity and purity of the drug. A UV Spectrophotometer was employed in the analytical procedure. Chitosan nanoparticles loaded with bupropion HCl were made using the ionic gelation method, and then the optimized batch was made using simulated in-situ gelation. Utilizing Central composite design, optimization was done by Design Expert-13. Evaluation of polymeric nanoparticles was performed by measuring their particle size, PDI, and entrapment efficiency.

Additionally, they were tested for drug release in vitro. The final nanoparticles were subsequently tested for gelation using nasal simulation fluid, and an ex vivo investigation was also conducted. An ion-sensitive polymer gellan gum was used as a gelling agent, which formed an immediate gel and remained for an extended period. The finished formulation was also subjected to several characterizations, including TEM and FTIR.

Results: The developed formulation was stable and showed enhanced contact time in the nasal mucosa, minimizing the frequency of administration. In-vitro studies through Franz diffusion cell and Ex-vivo studies on sheep nasal mucosa showed good results. In the Histopathological study, the optimized batch was found to be safe and stable in an accelerated stability study for one month.

Conclusion: Bupropion HCl-loaded chitosan nanoparticles In-situ gel proved to be suitable for the administration of Bupropion HCl through the nasal route. The ease of administration coupled with less frequent administration enhanced patient compliance. The formulation was found to be liquid at the formulated condition and formed gel in the presence of ions present in the nasal mucosa. The gel formed in situ showed sustained drug release. The formulations were less viscous before instillation and formed a strong gel after instilling in the nasal cavity.

« Previous Next »
Graphical Abstract

[1]
Office US. Interventions for smoking cessation and treatments for nicotine dependence. In: Smoking Cessation: A Report of the Surgeon General. Washington (DC) 2020.
[2]
Marcus M, Yasamy MT, van Ommeren MV, Chisholm D, Saxena S. Depression: A global public health concern. Available from: https://psycnet.apa.org/record/517532013-004?doi=1
[3]
Raj R, Wairkar S, Sridhar V, Gaud R. Pramipexole dihydrochloride loaded chitosan nanoparticles for nose to brain delivery: Development, characterization and in vivo anti-Parkinson activity. Int J Biol Macromol 2018; 109: 27-35.
[http://dx.doi.org/10.1016/j.ijbiomac.2017.12.056] [PMID: 29247729]
[4]
Nimi TN, Manohar DR. An overview on in-situ nasal gel for drug delivery. J Pharmaceut Sci Res 2019; 11(7): 2585-9.
[5]
Mistry A, Stolnik S, Illum L. Nanoparticles for direct nose-to-brain delivery of drugs. Int J Pharm 2009; 379(1): 146-57.
[http://dx.doi.org/10.1016/j.ijpharm.2009.06.019] [PMID: 19555750]
[6]
Zaki NM, Awad GA, Mortada ND, Abd ElHady SS. Enhanced bioavailability of metoclopramide HCl by intranasal administration of a mucoadhesive in situ gel with modulated rheological and mucociliary transport properties. Eur J Pharm Sci 2007; 32(4-5): 296-307.
[http://dx.doi.org/10.1016/j.ejps.2007.08.006] [PMID: 17920822]
[7]
Karpagavalli L, Gopalasrsatheeskumar K, Narayanan N, Maheswaran A, Raj AI, Priya JH. Formulation and evaluation of zolpidem nasal in situ gel. World J Pharm Res 2017; 6(2)
[8]
Behl CR, Pimplaskar HK, Sileno AP, deMeireles J, Romeo VD. Effects of physicochemical properties and other factors on systemic nasal drug delivery. Adv Drug Deliv Rev 1998; 29(1-2): 89-116.
[http://dx.doi.org/10.1016/S0169-409X(97)00063-X] [PMID: 10837582]
[9]
Sundar S, Kundu J, Kundu SC. Biopolymeric nanoparticles. Sci Technol Adv Mater 2010; 11(1): 014104.
[http://dx.doi.org/10.1088/1468-6996/11/1/014104] [PMID: 27877319]
[10]
Perry JL, Reuter KG, Kai MP, et al. PEGylated PRINT nanoparticles: The impact of PEG density on protein binding, macrophage association, biodistribution, and pharmacokinetics. Nano Lett 2012; 12(10): 5304-10.
[http://dx.doi.org/10.1021/nl302638g] [PMID: 22920324]
[11]
Rampino A, Borgogna M, Blasi P, Bellich B, Cesàro A. Chitosan nanoparticles: Preparation, size evolution and stability. Int J Pharm 2013; 455(1-2): 219-28.
[http://dx.doi.org/10.1016/j.ijpharm.2013.07.034] [PMID: 23886649]
[12]
Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Préat V. PLGA-based nanoparticles: An overview of biomedical applications. J Control Release 2012; 161(2): 505-22.
[http://dx.doi.org/10.1016/j.jconrel.2012.01.043] [PMID: 22353619]
[13]
Ismik D, Mansuroglu DS. Buluş E, Sahin YM. The use of chitosan nanoparticles obtained by ionic gelation method as a drug delivery system. J Mater Elec Devices 2020; 5(1): 6-11.
[14]
Chawla SP, Kanatt SR, Sharma AK. Food technology division, Bhabha Atomic Research Centre, Mumbai, India. Available from: https://www.barc.gov.in/div/66_207.html
[15]
Sutanto H, Suzery M, Adetya NP, Nilamsari AM, Yunanda A. Utilization of carrageenan and chitosan as coating material in phycocyanin encapsulation. IOP Conf Ser: Mater Sci Eng 2019; 633(1): 012038.
[16]
Warnken ZN, Smyth HDC, Watts AB, Weitman S, Kuhn JG, Williams RO III. Formulation and device design to increase nose to brain drug delivery. J Drug Deliv Sci Technol 2016; 35: 213-22.
[http://dx.doi.org/10.1016/j.jddst.2016.05.003]
[17]
Fan W, Yan W, Xu Z, Ni H. Formation mechanism of monodisperse, low molecular weight chitosan nanoparticles by ionic gelation technique. Colloids Surf B Biointerfaces 2012; 90: 21-7.
[http://dx.doi.org/10.1016/j.colsurfb.2011.09.042] [PMID: 22014934]
[18]
Houdi AA, Hussain AA. Method for enhanced brain delivery of bupropion. United States patent US 6,150,420, 2000.
[19]
Misra A, Kher G. Drug delivery systems from nose to brain. Curr Pharm Biotechnol 2012; 13(12): 2355-79.
[http://dx.doi.org/10.2174/138920112803341752] [PMID: 23016642]
[20]
Nagavarma BV, Yadav HK, Ayaz AV, Vasudha LS, Shivakumar HG. Different techniques for preparation of polymeric nanoparticles-a review. Asian J Pharm Clin Res 2012; 5(3): 16-23.
[21]
Agarwal M, Agarwal MK, Shrivastav N, Pandey S, Das R, Gaur P. Preparation of chitosan nanoparticles and their in-vitro characterization. Int J Life-Sci Scientific Res 2018; 4(2): 1713-20.
[http://dx.doi.org/10.21276/ijlssr.2018.4.2.17]
[22]
Salunke SR, Patil SB. Ion activated in situ gel of gellan gum containing salbutamol sulphate for nasal administration. Int J Biol Macromol 2016; 87: 41-7.
[http://dx.doi.org/10.1016/j.ijbiomac.2016.02.044] [PMID: 26899173]
[23]
Galgatte UC, Kumbhar AB, Chaudhari PD. Development of in situ gel for nasal delivery: Design, optimization, in vitro and in vivo evaluation. Drug Deliv 2014; 21(1): 62-73.
[http://dx.doi.org/10.3109/10717544.2013.849778] [PMID: 24191774]
[24]
Mehra M, Sheorain J, Kumari S. Synthesis of berberine loaded polymeric nanoparticles by central composite design. AIP Conf Proc 2016; 1724(1): 020060.
[25]
Crucho CIC, Barros MT. Polymeric nanoparticles: A study on the preparation variables and characterization methods. Mater Sci Eng C 2017; 80: 771-84.
[http://dx.doi.org/10.1016/j.msec.2017.06.004] [PMID: 28866227]
[26]
Deepika D, Dewangan HK, Maurya L, Singh S. Intranasal drug delivery of Frovatriptan succinate-loaded polymeric nanoparticles for brain targeting. J Pharm Sci 2019; 108(2): 851-9.
[http://dx.doi.org/10.1016/j.xphs.2018.07.013] [PMID: 30053555]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy